Point of use production of liposomal solubilised products

Swapnil Khadke, Peter Stone, Aleksey G. Rozhin, Jerome Kroonen, Yvonne Perrie

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Both the pre-clinical development and clinical use of many drugs remains hindered by their low solubility. Indeed, the ability to produce medicines in a liquid format remains a major consideration in pediatric and children’s medicines. Liquid dosage forms can also offer advantages as age-appropriate formulations, they offer flexibility in dosing and provide wider options for those who suffer from dysphagia. Tablets in particular can cause issues for paediatric dosing; for example, the World Health Organization noted that 4 children under 36 months in age died due to choking in a deworming campaign in Ethiopia during 2007 (WHO, 2007). They also noted that medical personnel are having to either break up tablets, dissolve them in solvents, or administer the powder contained in a capsule to young children as a relevant liquid drug delivery system isn’t available for that drug. However, there are a number of risks associated with these methods including difficulties in splitting and dividing of tablet doses and ensuring the drug can be reconstituted in water in a homogeneous system. Therefore, new solutions for such medicines are needed to overcome these issues.
LanguageEnglish
Pages1-8
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume537
Issue number1-2
Early online date8 Dec 2017
DOIs
Publication statusPublished - 15 Feb 2018

Fingerprint

Tablets
Pharmaceutical Preparations
Pediatrics
Ethiopia
Dosage Forms
Airway Obstruction
Drug Delivery Systems
Deglutition Disorders
Powders
Solubility
Capsules
Water

Keywords

  • liposomes
  • solubilisation
  • low solubility drugs
  • sonication
  • personalised formulation
  • rapid screening

Cite this

Khadke, Swapnil ; Stone, Peter ; Rozhin, Aleksey G. ; Kroonen, Jerome ; Perrie, Yvonne. / Point of use production of liposomal solubilised products. In: International Journal of Pharmaceutics. 2018 ; Vol. 537, No. 1-2. pp. 1-8.
@article{a810e1b53c8745a5ae17066635c7575e,
title = "Point of use production of liposomal solubilised products",
abstract = "Both the pre-clinical development and clinical use of many drugs remains hindered by their low solubility. Indeed, the ability to produce medicines in a liquid format remains a major consideration in pediatric and children’s medicines. Liquid dosage forms can also offer advantages as age-appropriate formulations, they offer flexibility in dosing and provide wider options for those who suffer from dysphagia. Tablets in particular can cause issues for paediatric dosing; for example, the World Health Organization noted that 4 children under 36 months in age died due to choking in a deworming campaign in Ethiopia during 2007 (WHO, 2007). They also noted that medical personnel are having to either break up tablets, dissolve them in solvents, or administer the powder contained in a capsule to young children as a relevant liquid drug delivery system isn’t available for that drug. However, there are a number of risks associated with these methods including difficulties in splitting and dividing of tablet doses and ensuring the drug can be reconstituted in water in a homogeneous system. Therefore, new solutions for such medicines are needed to overcome these issues.",
keywords = "liposomes, solubilisation, low solubility drugs, sonication, personalised formulation, rapid screening",
author = "Swapnil Khadke and Peter Stone and Rozhin, {Aleksey G.} and Jerome Kroonen and Yvonne Perrie",
year = "2018",
month = "2",
day = "15",
doi = "10.1016/j.ijpharm.2017.12.012",
language = "English",
volume = "537",
pages = "1--8",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
number = "1-2",

}

Point of use production of liposomal solubilised products. / Khadke, Swapnil; Stone, Peter ; Rozhin, Aleksey G.; Kroonen, Jerome ; Perrie, Yvonne.

In: International Journal of Pharmaceutics, Vol. 537, No. 1-2, 15.02.2018, p. 1-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Point of use production of liposomal solubilised products

AU - Khadke, Swapnil

AU - Stone, Peter

AU - Rozhin, Aleksey G.

AU - Kroonen, Jerome

AU - Perrie, Yvonne

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Both the pre-clinical development and clinical use of many drugs remains hindered by their low solubility. Indeed, the ability to produce medicines in a liquid format remains a major consideration in pediatric and children’s medicines. Liquid dosage forms can also offer advantages as age-appropriate formulations, they offer flexibility in dosing and provide wider options for those who suffer from dysphagia. Tablets in particular can cause issues for paediatric dosing; for example, the World Health Organization noted that 4 children under 36 months in age died due to choking in a deworming campaign in Ethiopia during 2007 (WHO, 2007). They also noted that medical personnel are having to either break up tablets, dissolve them in solvents, or administer the powder contained in a capsule to young children as a relevant liquid drug delivery system isn’t available for that drug. However, there are a number of risks associated with these methods including difficulties in splitting and dividing of tablet doses and ensuring the drug can be reconstituted in water in a homogeneous system. Therefore, new solutions for such medicines are needed to overcome these issues.

AB - Both the pre-clinical development and clinical use of many drugs remains hindered by their low solubility. Indeed, the ability to produce medicines in a liquid format remains a major consideration in pediatric and children’s medicines. Liquid dosage forms can also offer advantages as age-appropriate formulations, they offer flexibility in dosing and provide wider options for those who suffer from dysphagia. Tablets in particular can cause issues for paediatric dosing; for example, the World Health Organization noted that 4 children under 36 months in age died due to choking in a deworming campaign in Ethiopia during 2007 (WHO, 2007). They also noted that medical personnel are having to either break up tablets, dissolve them in solvents, or administer the powder contained in a capsule to young children as a relevant liquid drug delivery system isn’t available for that drug. However, there are a number of risks associated with these methods including difficulties in splitting and dividing of tablet doses and ensuring the drug can be reconstituted in water in a homogeneous system. Therefore, new solutions for such medicines are needed to overcome these issues.

KW - liposomes

KW - solubilisation

KW - low solubility drugs

KW - sonication

KW - personalised formulation

KW - rapid screening

U2 - 10.1016/j.ijpharm.2017.12.012

DO - 10.1016/j.ijpharm.2017.12.012

M3 - Article

VL - 537

SP - 1

EP - 8

JO - International Journal of Pharmaceutics

T2 - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -